<SEC-DOCUMENT>0001185185-22-000608.txt : 20220512
<SEC-HEADER>0001185185-22-000608.hdr.sgml : 20220512
<ACCEPTANCE-DATETIME>20220512164926
ACCESSION NUMBER:		0001185185-22-000608
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20220510
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220512
DATE AS OF CHANGE:		20220512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			India Globalization Capital, Inc.
		CENTRAL INDEX KEY:			0001326205
		STANDARD INDUSTRIAL CLASSIFICATION:	WHOLESALE-ELECTRONIC PARTS & EQUIPMENT, NEC [5065]
		IRS NUMBER:				202760393
		STATE OF INCORPORATION:			MD
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32830
		FILM NUMBER:		22918634

	BUSINESS ADDRESS:	
		STREET 1:		10224 FALLS ROAD
		CITY:			POTOMAC
		STATE:			MD
		ZIP:			20854
		BUSINESS PHONE:		301-983-0998

	MAIL ADDRESS:	
		STREET 1:		10224 FALLS ROAD
		CITY:			POTOMAC
		STATE:			MD
		ZIP:			20854
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>indiaglob20220512_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu May 12 20:32:43 UTC 2022 -->
<html xmlns:compsci="http://compsciresources.com" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:igc="http://www.igcinc.us/20220510" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xml="http://www.w3.org/XML/1998/namespace"><head>
	<title>indiaglob20220512_8k.htm</title>

	<!-- Generated by ThunderDome Portal - 5/12/2022 8:26:22 PM -->

<meta content="text/html" http-equiv="Content-Type" />
</head>
<body><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div>
</div><hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"/><div>
</div><hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0"/><div>
</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 15pt;"><b>UNITED STATES</b></p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 15pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 15pt;"><b>Washington, D.C. 20549</b></p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 15pt;">&#160;</p><div>

</div><hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 0pt auto 0pt auto;"/><div>
</div><p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 15pt;">&#160;</p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 15pt;"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType">8-K</ix:nonNumeric></b></p><div>

</div><p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 15pt;">&#160;</p><div>

</div><hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 0pt auto 0pt auto;"/><div>
</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 15pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 15pt;"><b>CURRENT REPORT</b></p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 15pt;"><b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 15pt;">Date of report (Date of earliest event reported):&#160;&#160;<ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate">May 10, 2022</ix:nonNumeric></p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><div style="text-align: center;"><img alt="picture2.jpg" src="picture2.jpg"/></div><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 15pt;"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName"><b><span style="text-decoration:underline">India Globalization Capital, Inc.</span></b></ix:nonNumeric></p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 15pt;">(Exact Name of Registrant as Specified in Its Charter)</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">	<tr>	<td style="vertical-align:top;width:22.8%;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 9pt;"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><b><span style="text-decoration:underline">Maryland</span></b></ix:nonNumeric></p>	</td>	<td style="vertical-align: top; width: 22.8%; text-align: center;"><ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber"><span style="text-decoration:underline"><b>001-32830</b></span></ix:nonNumeric></td>	<td style="vertical-align:top;width:22.8%;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 18pt;"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber"><b><span style="text-decoration:underline">20-2760393</span></b></ix:nonNumeric></p>	</td>	</tr>	<tr>	<td style="vertical-align:top;width:22.8%;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 9pt;">(State or other jurisdiction of incorporation)&#160;</p>	</td>	<td style="vertical-align: top; width: 22.8%; text-align: center;">(Commission File Number)</td>	<td style="vertical-align:top;width:22.8%;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 18pt;">(I.R.S Employer Identification Number)</p>	</td>	</tr>
</table><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">	<tr>	<td style="width: 50%; text-align: center;">	<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1"><b>10224 Falls Road</b></ix:nonNumeric></p>	<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><span style="text-decoration:underline"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown">Potomac</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Maryland</ix:nonNumeric></span></b></p>	</td>	<td style="width: 50%; text-align: center; vertical-align: bottom;"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode"><b><span style="text-decoration:underline">20854</span></b></ix:nonNumeric></td>	</tr>	<tr>	<td style="text-align: center;">(Address of Principal Executive Offices)&#160;</td>	<td style="text-align: center;">(Zip Code)</td>	</tr>
</table><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 17pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 17pt;">Registrant&#8217;s telephone number, including area code:<b> <ix:nonNumeric contextRef="c0" name="dei:CityAreaCode">(301)</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber">983-0998</ix:nonNumeric></b></p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><span style="text-decoration:underline"><b>Not Applicable</b></span></p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">(Former Name or Former Address, if Changed Since Last Report)</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the follow provisions:</p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">	<tr>	<td style="vertical-align: top; width: 35%; border-top: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-image: initial;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Title of each class</p>	</td>	<td style="vertical-align: top; width: 30%; border-top: 1px solid rgb(0, 0, 0); border-image: initial;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Trading Symbol(s)</p>	</td>	<td style="vertical-align: top; width: 35%; border-top: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-image: initial;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Name of each exchange on which registered</p>	</td>	</tr>	<tr>	<td style="vertical-align: top; width: 35%; border: 1px solid rgb(0, 0, 0);">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle">Common Stock, $.0001 par value</ix:nonNumeric></p>	</td>	<td style="vertical-align: top; width: 30%; border-top: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0); border-image: initial;">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol">IGC</ix:nonNumeric></p>	</td>	<td style="vertical-align: top; width: 35%; border: 1px solid rgb(0, 0, 0);">	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NYSE American</ix:nonNumeric></p>	</td>	</tr>
</table><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter)</p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Emerging growth company&#160;<ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric>.</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#160;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 15pt;"><b>CURRENT REPORT ON FORM 8-K</b></p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 17pt;"><b>India Globalization Capital, Inc.</b></p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 17pt;"><b>May 10, 2022</b></p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Item 1.01 Entry Into a Material Definitive Agreement</b></p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">On May 10, 2022, a License Agreement (the &#8220;License Agreement&#8221;) was entered into by and between Jawaharlal Nehru Centre for Advanced Scientific Research (&#8220;JNCASR&#8221;), Bengaluru (&#8220;Licensor&#8221;) and Hamsa Biopharma India Private Limited, Delhi (&#8220;Licensee&#8221;). As a result of the License Agreement there was a transfer of rights of a proprietary technology and know-how of certain patents and patent filings relating to small molecule inhibitors with a naphthalene monoamide scaffold (&#8220;NMI Compounds&#8221;).</p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The NMI Compounds, to which we have the rights to, can potentially, but there can be no assurance thereof, ameliorate in vitro and in vivo amyloid induced neurotoxicity, which are prospective candidates to treat certain nervous system disorders in humans, including Alzheimer&#8217;s Disease; and/or may have other pharmacological or non-pharmacological benefits and applications.</p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The JNCASR is an autonomous institution under the Department of Science and Technology, Government of India, an institution deemed to be a University, having its office at Bangalore Karnataka, India. Hamsa Biopharma India Private Limited is a wholly owned subsidiary of India Globalization Capital Inc. (NYSE:IGC).</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Item 9.01 Financial Statement and Exhibits.</b></p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p><div>

</div><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">(d) Exhibits.</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 108px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration:underline">Exhibit No.</span></b></p>
			</td>
			<td style="vertical-align: middle; width: 1647px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration:underline">Description</span></b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 108px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">10.1&#160;</p>
			</td>
			<td style="vertical-align: middle; width: 1647px; text-align: justify;"><a href="ex_374886.htm" style="-sec-extract:exhibit;">License Agreement entered into on May 10, 2022 by and between Jawaharlal Nehru Centre For Advanced Scientific Research, Bengaluru and Hamsa Biopharma India Private Limited, Delhi.<sup style="vertical-align:top;line-height:120%;font-size:pt">1</sup></a></td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 108px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">104</p>
			</td>
			<td style="vertical-align: middle; width: 1647px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL)</p>
			</td>
		</tr>

</table><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:9pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">1</sup></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K because they are both (i) not material and (ii) the type that the registrant treats as private or confidential. A copy of the omitted portions will be furnished to the SEC upon its request.</p>
			</td>
		</tr>

</table><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#160;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 15pt;text-indent:36pt;"><b>SIGNATURES</b></p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:36pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:22.8%;">&#160;</td>
			<td colspan="2" style="vertical-align:top;width:17.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>INDIA GLOBALIZATION CAPITAL, INC.</b></p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:22.8%;">&#160;</td>
			<td colspan="2" style="vertical-align:top;width:17.4%;">&#160;</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:22.8%;">&#160;</td>
			<td style="vertical-align:top;width:1.4%;">&#160;</td>
			<td style="vertical-align:top;width:16%;">&#160;</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:22.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dated:&#160;&#160;May 12, 2022</p>
			</td>
			<td style="vertical-align:top;width:1.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:16%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/&#160;Claudia Grimaldi</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:22.8%;">&#160;</td>
			<td style="vertical-align:top;width:1.4%;">&#160;</td>
			<td style="vertical-align:bottom;width:16%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Name:&#160;Claudia Grimaldi</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:22.8%;">&#160;</td>
			<td style="vertical-align:top;width:1.4%;">&#160;</td>
			<td style="vertical-align:top;width:16%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Title:&#160;Principal Financial Officer, Chief Compliance Officer, and Vice President</p>
			</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:22.8%;">&#160;</td>
			<td style="vertical-align:top;width:1.4%;">&#160;</td>
			<td style="vertical-align:top;width:16%;">&#160;</td>
			<td style="vertical-align:top;width:5.5%;">&#160;</td>
		</tr>

</table><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><div>

</div><div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>
</div><div>


</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey">0001326205</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="igc-20220510.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><xbrli:context id="c0">
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt9uvRsJTXMeMewLyH9HKj6I6pbvcDxjLALOm5tfIsNSqwD4AozZ/F944Y87fOfI0y4QCn3wy0vWYacVKSOrI2x+57PzV6dxHY+DksXOKRKrCCwlGtYVte/lmEdNsKZGNn+KaDdv4qKu3C7ES51S6WuFUqZ7ToeJ7/ndOpIznR0CQTFvzt326Z2MBiKFRq5ekGBB4n1L3987lo5i3/c5UaGE] CSR-->
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326205</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-05-10</xbrli:startDate>
    <xbrli:endDate>2022-05-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context></ix:resources></ix:header>

</div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex_374886.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html><head>
	<title>ex_374886.htm</title>
	<!-- Generated by ThunderDome Portal - 5/12/2022 8:35:24 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 8pt;"><b>EXHIBIT 10.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>[***]</b> <b>Certain information has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K from this document because it is both not material and is the type that the registrant treats as private or confidential.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>LICENSE AGREEMENT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">BY AND BETWEEN</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH (&#8220;JNCASR&#8221;), BENGALURU</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(</b>&#8220;<b>LICENSOR</b>&#8221;<b>) </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>AND</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">HAMSA BIOPHARMA INDIA PRIVATE LIMITED, DELHI</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(</b>&#8220;<b>LICENSEE</b>&#8221;<b>)</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Table of Contents</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:bottom;width:90.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Section 1 - Definitions:</i></p>
			</td>
			<td style="vertical-align:bottom;width:10.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><i>4</i></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:90.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Section 2 - Patent Filings:</i></p>
			</td>
			<td style="vertical-align:bottom;width:10.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><i>6</i></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:90.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Section 3 - License Grant, First Right of Refusal:</i></p>
			</td>
			<td style="vertical-align:bottom;width:10.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><i>6</i></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:90.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Section 4 - Data on NMI Compounds:</i></p>
			</td>
			<td style="vertical-align:bottom;width:10.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><i>7</i></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:90.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Section 5 - Improvements:</i></p>
			</td>
			<td style="vertical-align:bottom;width:10.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><i>7</i></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:90.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Section 6 - License Fee and Royalty:</i></p>
			</td>
			<td style="vertical-align:bottom;width:10.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><i>7</i></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:90.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Section 7 - Patent Infringement:</i></p>
			</td>
			<td style="vertical-align:bottom;width:10.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><i>9</i></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:90.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Section 8 - Acquisition, Restructuring, and Sub-licensing terms:</i></p>
			</td>
			<td style="vertical-align:bottom;width:10.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><i>10</i></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:90.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Section 9 - Term and Termination:</i></p>
			</td>
			<td style="vertical-align:bottom;width:10.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><i>10</i></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:90.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Section 10 - Disclosure and Confidentiality:</i></p>
			</td>
			<td style="vertical-align:bottom;width:10.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><i>11</i></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:90.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Section 11 - Dispute Resolution:</i></p>
			</td>
			<td style="vertical-align:bottom;width:10.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><i>11</i></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:90.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Section 12 - Miscellaneous:</i></p>
			</td>
			<td style="vertical-align:bottom;width:10.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><i>12</i></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:90.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Section 13 - General Provisions:</i></p>
			</td>
			<td style="vertical-align:bottom;width:10.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><i>13</i></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:90.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Section 14 - Severability:</i></p>
			</td>
			<td style="vertical-align:bottom;width:10.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><i>15</i></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:90.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Signatures:</i></p>
			</td>
			<td style="vertical-align:bottom;width:10.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><i>15</i></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:90.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:10.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:90.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:10.5%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>License Agreement</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;">This License Agreement [hereinafter referred to as the &#8220;Agreement&#8221;] is made effective on the date of the last signature below by the Parties (the &#8220;<b>Effective Date</b>&#8221;),</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Between</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;"><b>Jawaharlal Nehru Centre for Advanced Scientific Research (</b>&#8220;<b>JNCASR</b>&#8221;<b>)</b>, an autonomous institution under the Department of Science and Technology, Government of India, an institution deemed to be a University, having its office at Jakkur, Bangalore 560064, Karnataka, India, represented by Mr. Joydeep Deb, who is duly authorized and empowered by its Council of Management (which expression shall unless repugnant to the subject or context thereof, include its successors and permitted assigns) and hereinafter referred to as the &#8220;<b>Licensor</b>&#8221;.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>And</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;"><b>Hamsa Biopharma India Private Limited, </b>a Company duly incorporated under the Companies Act, 2013, having its registered office at D-Mall, Plot No A-1001, Netaji Subhash Place, Pitampura Delhi North Delhi DL- 110034, represented by its director/representative, who is authorized and empowered by its Board of Directors (which expression shall unless repugnant to the subject or context thereof, include its successors and permitted assigns) and hereinafter referred to as the &#8220;<b>Licensee</b>&#8221;.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;"><b>AND WHEREAS</b>, the Licensor and its Inventor, Professor Govindaraju Thimmaiah (hereinafter referred as &#8220;<b>PGT</b>&#8221;) have developed proprietary technology, know-how, and have ownership or assignment of certain patents and patent filings relating to small molecule inhibitors with a naphthalene monoamide scaffold (hereinafter referred as &#8220;<b>NMI Compounds</b>&#8221;): (a) that can ameliorate in vitro and in vivo amyloid induced neurotoxicity, which are prospective candidates to treat certain nervous system disorders in humans; or (b) which may have other pharmacological or non-pharmacological benefits and applications. The patent filings and patents are listed below and hereinafter, both individually and collectively, referred as the &#8220;<b>Patent</b>&#8221;:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:42pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">India Patent Application No. 202041031875 dated 24<sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup>&nbsp;July 2020, &#8220;Naphthalene Monoamide Compounds and Methods Thereof&#8221;;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:42pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">b)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">United States PCT Application No. PCT/IB2021/056633 dated 22<sup style="vertical-align:top;line-height:120%;font-size:pt">nd</sup>&nbsp;July 2021, Publication WO 2022/018679 A1 &#8220;Naphthalene monoamide compounds and methods thereof&#8221;;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:42pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">c)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">United States Patent No. US 9,230,708 B2 granted on January 5, 2016, WO2012098439A1 &#8220;Self Assembly of naphthalene diimide derivatives and process thereof&#8221;;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:42pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">d)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">India Patent Number 293450 granted on February 27, 2018. Application Number 159/CHE/2011 filed on January 17, 2011; &#8220;Self Assembly of Naphthalene Diimide Derivatives and Process Thereof&#8221;.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;"><b>AND WHEREAS </b>the Licensor has carried out animal studies using NMI Compounds and desires to carry out additional studies including but not limited to establish the safety and efficacy of NMI Compounds to treat Alzheimer&#8217;s disease (hereinafter referred as &#8220;<b>AD</b>&#8221;) and any and all other diseases, conditions, symptoms, and ailments, including Central Nervous System (CNS) disorders in humans and animals to support Investigational New Drug Applications (hereinafter referred as &#8220;<b>IND</b>&#8221;s) to the U.S. Food and Drug Administration (hereinafter referred as &#8220;<b>FDA</b>&#8221;) and other similar regulatory bodies and, if warranted, New Drug Applications (hereinafter referred as &#8220;<b>NDA</b>&#8221;s) to manufacture and sell NMI Compounds to treat AD, other diseases, conditions, symptoms, and ailments, including CNS disorders, whether in humans or in animals.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;"><b>AND WHEREAS</b>, herein, the Licensor and the Licensee are referred to individually as a &#8220;<b>Party</b>&#8221; and collectively as the &#8220;<b>Parties.</b>&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;"><b>NOW, THEREFORE</b>, the Parties, for good and valuable consideration and pursuant to a series of discussions, have decided to formalize their relationship through this Agreement on mutually agreed and legally binding terms and conditions which are set out hereinafter:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Section 1 </b>&#8211;<b> Definitions:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:6pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.1</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>&#8220;Research Program</b>&#8221;&nbsp;shall mean further research to be conducted by the Licensor in respect to NMI Compounds, including, without limitation: (a) to establish the commercial feasibility of obtaining FDA or other regulatory approval to sell NMI Compounds to treat human or animal diseases, conditions, symptoms, or ailments such as, but not limited to, AD and CNS disorders; (b) to establish the commercial feasibility of obtaining regulatory approval to sell NMI Compounds for any other legally permissible purpose, such as, but not limited to, as a dietary or other supplement or personal-use product; or (c) to establish the commercial feasibility to sell NMI Compounds for non-pharmacological purposes and applications.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:6pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.2</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>&#8220;Licensor Technology</b>&#8221;<b>&nbsp;</b>shall mean all data (including physical and electronic), discoveries, formulations, inventions, technical information, research papers, and know- how regarding NMI Compounds, disclosed to the Licensee hereunder and including Licensor Improvements.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:6pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.3</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>&#8220;Licensor Patent Rights</b>&#8221;&nbsp;shall mean the Patent and any patents that may be granted or have been granted based on the Licensed Technology, in any jurisdiction in the Licensed Territory, owned by Licensor, relating to NMI Compounds and includes all divisions, continuations, and continuations-in-part of any such application, all re-issues, re- examinations or extensions of any such patent.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:6pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.4</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>&#8220;Licensor Improvements</b>&#8221;<b>&nbsp;</b>shall mean any discovery or improvement relating to NMI Compounds, whether covered by the Patent or otherwise, made or acquired by the Licensor.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:6pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.5</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>&#8220;Licensed Product</b>&#8221;&nbsp;shall mean any compound, composition, formulation or other substance or concept, manufactured, used, offered for sale or sold by the Licensee using Licensor Technology, Licensor Patent Rights, or Licensor Improvements, where such manufacturing, using, offering to sell or selling, in the absence of a right or license, would infringe the Licensor Technology, Licensor Patent Rights, or Licensor Improvements.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:6pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.6</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>&#8220;Licensed Territory</b>&#8221;&nbsp;shall mean worldwide.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:6pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.7</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>&#8220;Licensed Field</b>&#8221;&nbsp;shall mean the use of NMI Compounds: (a) for treating humans or animals, including but not limited to, for any nervous system disorders; (b) for use on humans or animals for any other personal-, health-, wellbeing-, or life science-related purpose; or (c) for any non-pharmacological purpose or application.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:6pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.8</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>&#8220;Affiliate</b>&#8221;&nbsp;of a Party shall mean (i) any present or future domestic or foreign corporation, limited liability company, or other entity or person (a &#8220;<b>Person</b>&#8221;) at least twenty (20) percent of whose capital stock, equity, or voting rights, shall at the time be owned or controlled, directly or indirectly, including through joint venture, by such Party; (ii) any present or future Person that owns or controls, directly or indirectly, at least twenty (20) percent of the capital stock, equity or voting rights of such Party (each, a &#8220;<b>Parent</b>&#8221;); or (iii) any Person at least twenty (20) percent of whose capital stock, equity, or voting rights, shall at the time be owned or controlled, directly or indirectly, including through joint venture, by such Party&#8217;s Parent or any other Affiliate of the Party.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:6pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.9</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>&#8220;Net Revenue</b>&#8221;<b>&nbsp;</b>shall mean the gross amount of sales with respect to the Licensed Products shown on the invoice minus: (i) actual trade and cash discounts, and any uncollected amount (bad debt); (ii) credits or refunds allowed for spoiled, damaged, outdated, or returned Licensed Products; (iii) Goods and Service Tax [GST] and other similar statutory levies indicated in the invoice, collected and paid to the government, concerning the sale; and (iv) insurance and transportation costs to the extent separately invoiced, if any.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:6pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.10</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>&#8220;Inventor</b>&#8221;&nbsp;shall mean PGT.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:6pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.11</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>&#8220;INR</b>&#8221;&nbsp;denotes Indian Rupees.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:6pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.12</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>&#8220;Confidential Information</b>&#8221;&nbsp;shall mean and include the information disclosed by either Party to the other Party, and designated by the disclosing Party as proprietary and/or confidential, in writing, orally or visually. Included in Confidential Information, and not by way of limitation, are: (i) the existence of this Agreement; (ii) the understanding of the Parties as captured under this Agreement including the terms and conditions as</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">4</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify; vertical-align: top; text-indent: 0pt;">setout hereunder and the LOI; (iii) the fact of the evaluation of NMI Compounds; (iv) the Research Program and the protocol for same; and (v) the results of the Research Program and all reports.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:6pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.13</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>&#8220;Third Party</b>&#8221;&nbsp;shall mean a Person other than a Party or an Affiliate of a Party.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 2 </b>&#8211;<b> Patent Filings:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; vertical-align: top;">2.1 The Licensee shall, at its option and expense, through Counsel of its choice, during the Term and any period of time thereafter necessary to effectuate the terms of this Agreement, prosecute and maintain applications for the patent(s) covered by the Licensor Patent Rights in the appropriate territories from the Effective Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 3 - License Grant, First Right of Refusal:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:6pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(a)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Subject to the terms of this Agreement, the Licensor hereby grants to Licensee, and the Licensee hereby accepts, an exclusive, transferable, and sub-licensable license to manufacture, test, research, develop, investigate, make, have made, use, offer to sell, sell, export, and import (i) the Licensed Technology and (ii) the Licensed Products in the Licensed Field in the Licensed Territory using the Licensor Technology (the &#8220;<b>License</b>&#8221;).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:6pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(b)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Licensee shall have the right to assign, transfer, or sub-license any rights conferred upon the Licensee under paragraph (a) of this Section to its Affiliates or any Third Party provided, however, that any such sub-license shall be subject, in all respects, to the restrictions, exceptions and termination provisions contained in this Agreement, and binding on the Licensee. The Licensee shall, within seven (7) days following such transfer or sub-license to its Affiliates or any Third Party, provide notice in writing to the Licensor in respect of the same.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:6pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(c)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Notwithstanding anything to the contrary in this Agreement or in any other agreement between the Parties, the Licensor shall grant the Licensee a First Right of Refusal (FRR) for all future inventions or discoveries related to (i) the treatment of Central Nervous System disorders, and in particular to AD, unrelated to the Licensed Technology or (ii) NMI Compounds contemplated by the Research Program.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:6pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(d)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Notwithstanding anything to the contrary in this Agreement, Licensee shall own all right, title, and interest in and to each compound, composition, formulation or other substance or concept created or developed independently by Licensee using Licensor Technology (the &#8220;<b>Licensee Technology</b>&#8221;), and Licensor grants to Licensee a limited, irrevocable, perpetual, fully paid-up, worldwide license to use, perform, display, execute, reproduce, distribute, transmit, modify (including to create derivative works), import, make, have made, sell, offer to sell, and otherwise exploit any Licensor Technology or Licensor Product to the extent incorporated in, combined with, or otherwise necessary for the use of, the Licensee Technology.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 4 - Data on NMI Compounds:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:6pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(a)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Licensor shall deliver to Licensee all Licensor Technology, including the raw data related to NMI Compounds, including but not limited to slides, presentation materials, brochures, advertisements, publications, graphics, reports, conference posters, or other documents from all studies conducted by the Licensor, whether kept in digital and/or non- digital mode, within fifteen (15) calendar days from the Effective Date of the Agreement.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:6pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">b)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Licensee shall have the complete right to use the NMI Compounds and all Licensor Technology as Licensee deems fit including but not limited to all purposes described herein and, for example, conducting clinical trials.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 5 </b>&#8211;<b> Improvements:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 6pt; text-align: justify;">The Licensor shall promptly (as soon as reasonably practicable) disclose Licensor Improvements to the Licensee, and such Licensor Improvements shall become part of the Licensor Technology.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">5</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 6 </b>&#8211;<b> License Fee and Royalty:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u><b>6.1- License Fee:</b></u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:34pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">For the License granted under this Agreement, the Licensee shall pay the Licensor a fee of INR [***] [INR [***] Only] (&#8220;<b>License Fee</b>&#8221;), plus applicable taxes, as the full and final initial consideration. The Licensor shall pay any statutory liabilities, including any charges or taxes that may be applicable based on its receipt of the License Fee.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:34pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">b)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The License Fee is payable as follows: (x) [***]percent ([***]%) of the License Fee is to be allocated to JNCASR and (y) the remaining [***]percent ([***]%) is to be allocated to PGT&#8217;s lab at JNCASR as an unrestricted research grant.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:34pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">c)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The License Fee is payable in two installments, the first INR [***] [INR [***] Only] shall be paid upon signing the Agreement; and the balance of INR [***] [INR [***]Only] shall be paid upon the approval of human clinical trial Phase II by the FDA for any clinical trial series for an IND for a formulation containing NMI Compounds.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u><b>6.2- Royalty:</b></u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:42pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In addition to the License fee payable under section 6.1, the Licensee shall also be liable to pay a royalty @ [***]% of the Net Revenue plus applicable taxes on any Licensed Product, to the Licensor (the &#8220;<b>Licensor Royalty</b>&#8221;).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:42pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">b)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Notwithstanding the foregoing, for any Licensee Technology, the Licensee shall also be liable to pay a royalty @ [***]% of the Net Revenue plus applicable taxes on any such product, to the Licensor (the &#8220;<b>Additional Royalty</b>&#8221;&nbsp;and together with the Licensor Royalty, the &#8220;<b>Royalties</b>&#8221;).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:42pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">c)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">For the duration of the Royalty Period (defined herein), Licensee shall pay Royalties to the Licensor in INR, within sixty (60) days following the end of June and December of each year, regardless of where the Licensed Product or Licensee Technology is made or sold and notwithstanding any currency restrictions or regulations in any country where the Licensed Product or Licensee Technology is sold. Each such payment shall be accompanied by a report certified by the Licensee setting out separately the Net Revenue of all Licensed Products and Licensee Technology sold during the said calendar six-month period.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:42pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">d)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">For sake of clarity, it is agreed between the Parties that the Royalty shall be payable only once on each sale or supply of the Licensed Product, regardless of the number of claims under which the Licensed Product may be covered in a patent or in multiple patents. For example, if three claims or three patents cover one product, there shall only be one royalty payment and not three.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:42pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">e)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Licensee and its Affiliates shall keep and maintain records for the sales and Net Revenue realized from the sale of the Licensed Products and Licensee Technology. Such records shall be open to inspection at any reasonable time during normal business hours. The inspection shall be permitted annually following the end of that financial year. The inspection may be carried out by an independent Chartered Accountant selected by the Licensor to whom the Licensee or its Affiliates have no reasonable objection. The inspection will be limited to the records related to this Agreement and sole as necessary to calculate the amount of Royalties and will not include the accounts of the Licensee as a whole or any other documents. The report of the Chartered Accountant shall be treated as confidential, and the expense of the inspection is to be borne by the Licensor.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:42pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">f)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Licensee&#8217;s obligation to pay the Royalty with respect to a Licensed Product or Licensee Technology shall commence from the date of FDA approval to market the Licensed Product or Licensee Technology as a pharmaceutical drug (the &#8220;<b>FDA Approval</b>&#8221;) and shall continue (i) for seven (7) years from the date of FDA Approval or (ii) until the expiration of the patent covering such Licensed Product or Licensee Technology, whichever is earlier (the &#8220;<b>Royalty Period</b>&#8221;).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">6</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:42pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">g)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If the Licensee is required to obtain license rights from any Third Party) in the Licensed Territory, or any portion thereof, in order to make or use or sell the Licensed Products, it may subtract from the royalty of [***]% payable under Para 6.2, the royalty payable to such third Party subject to a maximum of [***] percent ([***]%). For example, if the Licensee is required to pay XYZ Co. [***]% royalty to make or use or sell a Licensed Product, then the Licensee can subtract only [***]% from the [***]% royalty payable hereunder. If the royalty rate is [***]%, then the Licensee will pay a royalty of [***]% under this agreement. The Licensee will provide the Licensor with proof that any such third-party royalty was paid each time the Licensee claims a reduction hereunder.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:42pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">h)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If the validity, enforceability, and/or infringement of a patent included in the Licensor Patent Rights is challenged in any court of competent jurisdiction by any Third Party (an &#8220;Action&#8221;), or if the Licensee has reason to question the validity, enforceability and/or infringement of a patent included in the Licensor Patent Rights, the Parties then agree and acknowledge that the Royalty otherwise payable hereunder for the Licensed Products will be escrowed by the Licensee in an interest-bearing account in a bank or savings institution, provided, however: (i) The Licensee will first notify the Licensor in writing that it deems said claim or claims to be invalid, unenforceable and/or not infringed by virtue of such challenge or question; and (ii) no other claim or claims of Licensor Patent Rights not challenged or questioned covers the Licensed Product. Notice and the payment of Royalties into escrow by the Licensee as provided herein will not constitute a breach hereof and will not constitute grounds for the Licensor to otherwise terminate this Agreement.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:42pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">i)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If the Action is settled, or if a final decision upholds such patent and all appeals exhausted, all Royalties escrowed and interest thereon shall be paid to the Licensor within sixty (60) days of such final decision, and the Licensee shall thereafter continue to pay such Royalties to the Licensor hereunder. If such patent is found invalid, then escrowed Royalties and interest thereon will not be paid to the Licensor, (ii) such escrowed Royalties and interest thereon shall be retuned and paid to Licensee, and (iii) the license concerning such invalid patent will be terminated.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 7 - Patent Infringement:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:34pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If the Licensor or the Licensee determines that a Third Party is infringing a claim or claims of the patent within the Licensor Patent Rights, it will notify the other Party in writing as soon as practicable after discovery of the infringement. Should the Licensor elect to sue the alleged infringer in its own name and at its own expense, all recoveries in such suit shall inure to the benefit of the Licensor. If the Licensor determines that any Third Party infringed the claim(s) of the patent within the Licensed Patent Rights and Licensor did not disclose to the Licensee such infringement within thirty (30) days of discovery in writing, then, in that case, the Licensee shall have the right to commence such action at its own expense, and the Licensor agrees to join any such action as a necessary party to that. The Licensee will control any such action, and the Licensor may be represented by the counsel of its choice and cost. All recoveries in any such action commenced by the Licensee shall inure to the benefit of the Licensee.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:34pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">b)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If the Licensee or its Affiliate is sued by a Third Party for infringement of such Third Party&#8217;s patent resulting from the manufacture, use, offering to sell, or sale of the Licensed Product by the Licensee, or its Affiliate, the Licensee shall promptly notify the Licensor. During the pendency of the suit or legal proceeding, notwithstanding its right under Section 12(c), the Licensee shall have the right to apply the Royalties due to the Licensor against the Licensee&#8217;s litigation expenses in such suit or legal proceedings or to apply such Royalty amounts against any amount paid to a Third Party in settlement of such litigation provided that the Licensor consents to any such settlement in writing.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 8 -Acquisition, Restructuring, and Sub-licensing terms:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Restructuring: If at any time during the Term of the Agreement, the Licensee restructures its entity either by way of acquisition, sale, transfer, merger, amalgamation, compromise or arrangement, and/or any other way, and transfers the rights under the Agreement to the successor entity (a &#8220;<b>Corporate Successor</b>&#8221;), then the Corporate Successor shall be bound by the terms and conditions of the Agreement. The Licensee shall notify in writing the Licensor about such restructuring before completion of the restructuring.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">7</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">b)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Sub-License: The Licensee shall have the right to grant sub-licenses under the Agreement within the Licensed Field and Licensed Territory, provided that (a) the execution of a sub- license shall not diminish the Licensee&#8217;s obligations under the Agreement, and the Licensee shall remain primarily liable for such obligations and breach of any provision of the Agreement by any affiliate or sub-licensee of Licensee, and (b) the Licensee shall only grant a sub-license to a third party who undertakes to perform its obligations under the sub-license consistent with the terms and conditions of the Agreement. The Licensee shall notify in writing the Licensor of the details of such sub-licenses granted.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 9 </b>&#8211;<b> Term and Termination:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:34pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">This Agreement shall be valid from the Effective Date, and unless terminated earlier in accordance with this Section 9, will continue in full force and effect for each Licensed Product and the Licensed Technology and country in the Licensed Territory on a Licensed Product-by-Licensed Product and country-by-country basis until the expiration of the last to expire valid claim of a Licensed Product in such country (the &#8220;<b>Term</b>&#8221;).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:34pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">b)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Either Party may terminate this Agreement upon the material breach by the other Party of any of the terms and conditions contained in the Agreement after giving one hundred and twenty (120) days written notice of such termination (&#8220;<b>Notice Period</b>&#8221;). A statement of reasons for termination shall accompany such notice. However, if during the Notice Period, the breach is cured to the satisfaction of the non-breaching Party, then the Agreement shall continue in full force and effect.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If this Agreement is terminated by the Licensor, the Licensee shall promptly make available to the Licensor the record of the inventory of the Licensed Product which it and its Affiliates have on hand as of the date of such termination. The Licensee and its Affiliates shall then have the right, for a period of twelve (12) months after said termination, to sell such inventory provided that the Net Revenue thereof shall be subject to payment of Royalty by the Licensee at the rates set forth herein.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:34pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">c)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If the further lawful performance of this Agreement or any part hereof by either Party shall be rendered impossible by or as a consequence of any law, regulation, order, rule, direction, priority, seizure, allocation, requisition, or any other official action by any department, bureau, board, administration or other instrumentality or agency or any government or political subdivision thereof having jurisdiction over such Party, such Party shall not be considered in default hereunder by reason of any failure occasioned thereby.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:34pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">d)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The following provisions shall survive the termination of this Agreement: Sections 1, 2, 3(d), 7, 9, 10, 11, 12, 13, and 14.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 10 </b>&#8211;<b>&nbsp;Disclosure and Confidentiality:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>a)</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Confidentiality: <b>-</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 42pt;text-indent:26pt;">Neither this Agreement, nor its substance, nor any other Confidential Information disclosed hereunder, may be publicly or privately disclosed by any Party, or any of its Affiliates or representatives, except with the written consent of the other Party or as otherwise required under the law. If the either Party determines that it is required under the law to make such disclosure, then such Party shall first consult with the other Party before such disclosure, and the other Party shall cooperate to provide all such information required under the law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">b)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Publicity: -</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 42pt;text-indent:23pt;">The Parties agree and undertake that no press release or other public statement shall be issued by either Party relating to this Agreement or its contents unless required under the law. If either Party determines that it is necessary by law to make a public disclosure, it shall consult with the other Party before such disclosure and cooperate with the other Party to seek to avoid or minimize such disclosure.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 42pt;text-indent:23pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">8</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 11 </b>&#8211;<b>&nbsp;Dispute Resolution:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Arbitration Clause:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 24pt;text-indent:13pt;">If any dispute, difference, or question arises out of or in respect of the Agreement including any breach of any terms and conditions thereof, the same shall be referred to Arbitration. Each Party shall appoint one arbitrator, and the two appointed arbitrators shall appoint a third arbitrator.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 24pt;text-indent:13pt;">Arbitration shall commence in accordance with the provisions of the Arbitration and Conciliation Act, 1996. The place of Arbitrator shall be New Delhi, and the language shall be English.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">b)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Legal Expenses:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 24pt;text-indent:13pt;">Each Party shall bear its own the fees and expenses incurred in connection with the Agreement&#8217;s preparation, negotiation, and execution. Stamp duty, registration charges and other applicable statutory charges concerning the Agreement, if any, shall be borne equally by the Parties.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Section 12 </b>&#8211;<b>&nbsp;Miscellaneous:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Preferential Pricing</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 24pt; text-indent: 13pt; text-align: justify;">The Licensee shall endeavor to offer a preferential price or a discount for the Licensed Products sold or offered in India. The extent of preference or discount shall be at the sole discretion of the Licensee.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">b)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Current work and publications</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 24pt;text-indent:13pt;">The Licensee understands that Ph.D. students at JNCASR are currently working on research that overlaps with the License. The Licensee agrees that while the students may continue to work on their thesis, all publications, including poster presentations at a conference, are required to be approved by the Licensee prior to presentation or distribution to the publisher for publication. The Licensee agrees to engage with the Licensor, within 15 days of notification of publication, on the status of the approval, and that approval will be given within 30 days of such notification unless the Licensee notifies that such publication to be detrimental to its patent rights, as determined in its sole discretion.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">c)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indemnification</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 24pt;text-indent:13pt;">The Licensee shall defend, indemnify, and hold harmless and shall require all sub-licensees to defend, indemnify and hold harmless the Licensor, its Affiliates, and its and their respective board members, officers, and employees against any Third Party claim arising out of or related to the exercise of any rights granted to the Licensee under the Agreement or arising out of or related to the material breach of this Agreement by the Licensee. The Licensor shall defend, indemnify, and hold harmless the Licensee, its Affiliates, and its and their respective board members, officers, and employees against any claim (including all legal costs and expenses incurred by the Licensee) arising out of or related to (i) fraud, willful misconduct, gross negligence, or breach of any laws applicable from time to time, including anti-bribery and anti- corruption laws, by Licensor, its Affiliates, or any of its officers, employees, or other representatives, (ii) the infringement of any Third Party rights by the Licensed Product or the Licensed Technology, (iii) breach of any representation or warranty set forth in Section 12(e), or (iv) the material breach of this Agreement by the Licensor.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 24pt;text-indent:13pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="9" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">9</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">d)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Warranty</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 24pt;text-indent:13pt;">Except as set forth in Section 12(e), the Licensor, its administrators, board members, officers, employees, students, agents, and insurers make no representations and extend no warranties of any kind, either express or implied, including but not limited to warranties of merchantability; fitness for a particular purpose of the Licensed Products; and arising out of latent or other defects, whether or not discoverable. In no event shall the Licensor, its administrators, board members, officers, employees, students, agents, and insurers be liable for incidental or consequential damages of any kind, including economic damage or injury to property and lost profits.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">e)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Representations and Warranties</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 24pt;text-indent:13pt;">Licensor represents and warrants to Licensee that (a) Licensor is the owner of the entire right, title, and interest in and to the Licensed Products, Licensed Technology, and Licensed Patent Rights; (b) Licensor has not granted to any Third Party any licenses or other rights under any Licensed Product, Licensed Technology, or Licensed Patent Right that are in conflict with the terms and conditions of this Agreement; (c) the Patents are all the patents and patent applications owned by Licensor as of the Effective Date that are necessary for the manufacture, use, sale, offer for sale, or importation of any Licensed Product or Licensed Technology in the License Territory; (d) when used by Licensee in accordance with this Agreement, no Licensed Product, Licensed Technology, or Licensed Patent Right will infringe, misappropriate, or otherwise violate any intellectual property right or any other right of a Third Party; and (e) no expiration or loss of any Patent or Licensed Patent Right is pending, or, to Licensor&#8217;s knowledge after reasonable inquiry, threatened or reasonably foreseeable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Section 13 </b>&#8211;<b> General Provisions:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:34pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Neither Party shall use the name of the other in any advertising, packaging, or other promotional material in connection with the sale of Licensed Products without the consent of the other Party.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:34pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">b)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Neither Party shall unreasonably withhold its consent when such consent is requested in good faith by the other Party hereunder.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:34pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">c)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">This Agreement cannot be assigned by either Party without to the prior written consent of the other Party. Notwithstanding the foregoing, either Party may assign this Agreement to (x) a Corporate Successor of such Party, (y) an Affiliate of such Party, or (z) any Person acquiring all or substantially all the business or assets of such Party, in each case, without obtaining the other Party&#8217;s prior written consent.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:34pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">d)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Parties have entered into this Agreement in sound disposing state of mind, mutually, voluntarily and of their own will and volition and without any force, pressure, coercion and agree to be bound by the terms and conditions as stated above and shall not violate any conditions of this Agreement.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:34pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">e)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Agreement is executed in two copies and both copies are to be treated as original.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:34pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">f)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">All notices required to be given pursuant to this Agreement by each Party to the other shall be in writing and sent by electronic mail (delivery confirmation requested) and/or by Registered or Certified Mail and addressed, respectively, to the parties at the following:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">To Licensor:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Mr. Joydeep Deb,</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 90pt;">Administrative Officer,</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 90pt;">Jawaharlal Nehru Centre for Advanced Scientific Research Jakkur, Bangalore,</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 90pt;">Karnataka, India 560064</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 90pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">To Licensee:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Name: Claudia Grimaldi</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 90pt;">Designation: Director c/c Rohit Goel. Director</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 90pt;">Hamsa Biopharma India Private Limited</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 90pt;">D-Mall, Plot No A-1001, Netaji Subhash Place, Pitampura,</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 90pt;">Delhi North Delhi DL- 110034</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">Any notice shall be effective as of its date of receipt.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="10" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">10</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:34pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">g)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">This Agreement constitutes the entire Agreement between the parties and supersedes all written or oral prior agreements or understandings. No variation or modification of this Agreement shall be valid unless it is in writing and signed by the parties hereto.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:34pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">h)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">No right or license is granted by the Licensor under this Agreement to the Licensee, or by the Licensee to the Licensor, either expressly or by implication, except those specifically set forth herein.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:34pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">i)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Waiver by the Licensee or the Licensor of any single default or breach or succession of defaults or violations by the other shall not deprive the Licensor or the Licensee of any right to terminate this Agreement arising out of any subsequent default or breach.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:34pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">j)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">All matters affecting the interpretation, validity, and performance of this Agreement shall be governed by the laws of India applicable to agreements made and to be performed wholly within India, but the scope and validity of Licensor Patent Rights shall be governed by the applicable laws of the country granting the patent in question.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:34pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">k)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The captions herein are solely for convenience of reference and shall not affect the construction or interpretation of this Agreement.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Section 14 </b>&#8211;&nbsp;<b>Severability:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;">If any provision of this Agreement is held to be invalid or unenforceable, then such provision shall (so far as it is invalid or unenforceable) be given no effect and shall be deemed not to be included in this Agreement but without invalidating any of the remaining provisions of this Agreement. The Parties shall then use all reasonable endeavour to replace the invalid or unenforceable provision by a valid and enforceable substitute provision the effect of which is as close as possible to the intended effect of the invalid or unenforceable provision.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;">IN WITNESS WHEREOF, BOTH THE PARTIES HAVE SIGNED THIS AGREEMENT ON THE DAY, MONTH, YEAR IN THE PRESENCE OF THE FOLLOWING WITNESSES AFTER FULLY UNDERSTANDING THE CONTENTS, MEANING, AND PURPOSE OF THE PRESENT AGREEMENT.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;"><b>Signatures:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>For JNCASR, Jawaharlal Nehru Centre for Advanced Scientific Research</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">

		<tr>
			<td style="vertical-align:top;width:50.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">By <u>/s/&nbsp;Joydeep Deb&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">Name: Joydeep Deb</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">Designation: Administrative Officer</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">Date: <u>May 10, 2022&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</u></p>
			</td>
			<td style="vertical-align:top;width:50.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Witness: <u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp; &nbsp; &nbsp;</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>For Hamsa Biopharma India Private Limited</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">

		<tr>
			<td style="vertical-align:top;width:50.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">By&nbsp;<u>/s/ Rohit Goel&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">Witness: <u>Gourav Taneja&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">Name: Rohit Goel</p>
			</td>
			<td style="vertical-align:top;width:50.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">Designation: Director</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">Date:&nbsp;<u>March 21, 2022&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</u></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="11" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">11</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Acknowledged And Agreed:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">

		<tr>
			<td style="vertical-align:top;width:50.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">By&nbsp; <u>/s/&nbsp;Govindaraju Thimmaiah&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</u></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">&nbsp; &nbsp; &nbsp; &nbsp;Professor Govindaraju Thimmaiah</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">&nbsp; &nbsp; &nbsp; &nbsp;NCU, JNCASR Inventor&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">Date: <u>May 10, 2022&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</u></p>
			</td>
			<td style="vertical-align:top;width:50.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Witness: <u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>igc-20220510.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu May 12 20:32:43 UTC 2022 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2022" targetNamespace="http://www.igcinc.us/20220510" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:igc="http://www.igcinc.us/20220510" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="igc-20220510_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="igc-20220510_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="igc-20220510_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt9uvRsJTXMeMewLyH9HKj6I6pbvcDxjLALOm5tfIsNSqwD4AozZ/F944Y87fOfI0y4QCn3wy0vWYacVKSOrI2x+57PzV6dxHY+DksXOKRKrCCwlGtYVte/lmEdNsKZGNn+KaDdv4qKu3C7ES51S6WuFUqZ7ToeJ7/ndOpIznR0CQTFvzt326Z2MWSltNGUJ70A+7EHkD6u7utc8rHlbVz2Q] CSR-->
      <link:roleType roleURI="http://www.igcinc.us/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="igc_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>igc-20220510_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu May 12 20:32:43 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="igc-20220510.xsd#DocumentAndEntityInformation" roleURI="http://www.igcinc.us/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.igcinc.us/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="8" xbrldt:closed="true"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt9uvRsJTXMeMewLyH9HKj6I6pbvcDxjLALOm5tfIsNSqwD4AozZ/F944Y87fOfI0y4QCn3wy0vWYacVKSOrI2x+57PzV6dxHY+DksXOKRKrCCwlGtYVte/lmEdNsKZGNn+KaDdv4qKu3C7ES51S6WuFUqZ7ToeJ7/ndOpIznR0CQTFvzt326Z2MvJh+GMyDJhO6/IhFeemOFOw3RRjfVZti] CSR-->
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="22" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>igc-20220510_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu May 12 20:32:43 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt9uvRsJTXMeMewLyH9HKj6I6pbvcDxjLALOm5tfIsNSqwD4AozZ/F944Y87fOfI0y4QCn3wy0vWYacVKSOrI2x+57PzV6dxHY+DksXOKRKrCCwlGtYVte/lmEdNsKZGNn+KaDdv4qKu3C7ES51S6WuFUqZ7ToeJ7/ndOpIznR0CQTFvzt326Z2MwDULNtcEdTJUcz7rnh1pJzbuosIdsuJK] CSR-->
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl0" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl0" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl0" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl0" xml:lang="en-US">Pre-commencement Tender Offer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl0" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl0" xml:lang="en-US">Written Communications</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl0" xml:lang="en-US">Soliciting Material</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl0" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl0" xml:lang="en-US">Pre-commencement Issuer Tender Offer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>igc-20220510_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu May 12 20:32:43 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="igc-20220510.xsd#DocumentAndEntityInformation" roleURI="http://www.igcinc.us/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.igcinc.us/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="igc-20220510.xsd#igc_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt9uvRsJTXMeMewLyH9HKj6I6pbvcDxjLALOm5tfIsNSqwD4AozZ/F944Y87fOfI0y4QCn3wy0vWYacVKSOrI2x+57PzV6dxHY+DksXOKRKrCCwlGtYVte/lmEdNsKZGNn+KaDdv4qKu3C7ES51S6WuFUqZ7ToeJ7/ndOpIznR0CQTFvzt326Z2MtO7QmSFhxTU3xIwFTAdl3AgMUjn0l8lv] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>picture2.jpg
<TEXT>
begin 644 picture2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !9 &<# 2(  A$! Q$!_\0
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MG;NS@D9QVK\VO$W[0OQYT/\ ;(U+1;N:T\+6TTVG:'JAL[:?6-)T^V>0M!=
MG;LE=9G89"Y# .%VYKJOVS/VUM2^#_[3WP_M_"6IQZSH^B6,CZ_I5G<JT=V;
MF4+Y#D9VR(EN9%."02!CYL'VKP?^WM\$?%7BBQTKPS<ZCJ'B'Q#=11K;6>A3
MK-/,4"J96* 95%0%F. H7G:,UXV%P>)P=+ZQ+#^TC4CV^'7KIV5]OGHS7FN[
M7/IF-2D:J6+D#!9L9/N<<4ZBBODC0*YKXB?$30?A7X1OO$GB2^2PTNS7+,>7
MD8_=C1?XG8\ #^636-\9OC=X5^!/A1]<\3WOE*Q*6ME#AKB[D ^Y$F1GJ,DX
M SR17Y,_M#?M'>)OVB?%0U#5W^PZ7:EET_2(6)BM8S_%_M2-@98]>@   KFJ
MUE35EN?H/"O".)XBJJI.\*">LN_E'N_/9=>Q'^TA^T!K/[0WCN36M306>EVZ
MM!INEEBR6L+$=^C2-@%B!R0!P *_1W]A_P" ,WP1^%"W&L6Q@\5:^PO+^.10
M'MXQGR8#WRJG)!Z,[#MFOF']@3]E*7QCK=I\2O%-CL\.6,GF:1:3(5^VS@\3
M$'K&C#(_O,/12#]R?M _&K2/V?\ X4ZUXRU?]X+5/*L[1?OW=T_$,*C(R6;K
MZ ,>U3@\/.M--*\I;?/^M/\ (^JXZSS#4:4.'LLLJ5.W/;:ZVC?K;>7GYW.D
MT/Q[HWB+Q5XC\.Z?=>?J?A\VZZA&H^6)ID+HN?7:,D=LBBOBS_@E_P"(O$WC
MK5OBUXLUMY;F/5KVUEFO)!E9KHB5V5&(!*HDD:CT&T45[N8818'$RP][VM]]
MDW^)^)IW5SZ8_:$_9;^'_P"TMH(L?%^E9U"")H[+6K,^5>V8;J$DQRIYRC J
M<GC/-?@QXU\/CPKXQ\2:%]IDNO[+U"\T\7+(J-,D<QB\PKNP&"J<KNP PQU+
M'^D.O@WX*_\ !-FP?XR>,/B)\58;?5([K7[V^TGPY')YENR/.[1SW77>^&+!
M-Q W'/\ ='T_#V<QR^E56(FW%)<L=]==OUZ&%6'-:Q^4&GZM=:'KUO?6FU=4
ML;B&YMX9URN])-RJ4; =3Y:'&,?-VX4_NKXH\(:+^V[^SGX>OK7Q'K?AFWUN
MQCU"WO-#OI8#%(\>'CE0,%F56+*5?NO!'6O0_B)\#?A_\6;#['XO\'Z1KT6T
M(K75JOF(HZ!9!AE'T(J3X1?!_P -? WPC_PB_A&WGL= 2ZFNK>RFG:9;;S&W
M,D98E@FXD@$G!8\UEFN>TLPA2J4XN%6#TV:L]_TT:[ZCA3<6[['X0?&+X1ZA
M\#?BAKG@#4KFUU2\TF2.V%S9HP2X62)61@A&0Q&[*\\^<.=ZU]>_\$E)?"=Y
M\7_%OV^)+CQ9'I8DT>>0[EB@$FV["!LD3%FBW%3RAZ8)S]T:3^R3X+@_:$\0
M?&+5X?[=\3W\D+:?%=H#;Z5Y<,<6^%#D>:WE!C)U!)QCDE_Q8O?@I\$M>L_B
M%XILM$T;Q1:K(+.[M8%749]ZE&5$3#2@@D'(('&<8%=N/XDI8O"/#-.\HJ\E
MI[W73M?3]&:X?#5:U14Z,>:3V2W9[97S#^TM^W-X7^"_VG0O#OD^*?&:C:;>
M-BUI9MG_ );R*?O 9/EKSTR5R"?D/]H3_@H5XP^*K7&D^#UE\&^%VR-Z/C4+
ME2"")'!PBD<[4_%CV^5K6)I7CBB1I)&*QJJKEMQ.  ,<G@=LD@#V'YM4FTM-
M#]SX;X YI1Q.;[;\B?\ Z4_T7WG7?$+XG>)?BQXDN/$'BG5IM5U&7^-ON0J,
M'RD3HB\GY5 Z^O)^A_V._P!BV[^,EU;>*O%UO)8>!87S%;'*2ZFRD@!#CB($
M?,W4XVKW9?0?V5?^"?,]\;+Q5\5+1[2W7;+:^&&(5Y!C_EZ ^ZO0^7G/4-@9
M4_H*HM=)T\ "&RLK6+  Q''%&H_)5 'T %<U*ASOFFM#U.*>.*."H_V7DC2:
M7*Y1VBNT+:7\UHNFNU:>;2_"/A^2:0VND:+I=J79L+#!:V\:9)[!$55^@ K\
M6OVO_P!I37?VSOC5I>A>$+2ZN/#%K>#3?#>G!6/V^X=MANI$R0&8Y"D@;8U8
MY#!J[K_@H!^W<?C7J,WP^\!WTD?PZM9PFI:I"60:S*NX[%8$?Z.I7C^^PS@@
M"O9/^"7/[(+>'=-MOC)XQTWR]6O+?R_#EI<QX>UMRNU[DJ1D-)R$/:-B1@.
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MX2^$MU\/-4\%:;_PC=WK,EW;7UOIMQ)%!(L:Q>6WE*V%*^8XRH&1P>@KA?\
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9_+]T%>Y45Y=:M4Q$W4J.[_K9=$4E96/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140395009177272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>May 10, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">India Globalization Capital, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IGC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001326205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 10,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-32830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-2760393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10224 Falls Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Potomac<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(301)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">983-0998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $.0001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>indiaglob20220512_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="igc-20220510.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326205</identifier>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <dei:DocumentType contextRef="c0">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c0">2022-05-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c0">India Globalization Capital, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0">MD</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c0">001-32830</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c0">20-2760393</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0">10224 Falls Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c0">Potomac</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0">20854</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0">(301)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0">983-0998</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c0">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c0">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c0">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c0">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c0">Common Stock, $.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0">IGC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c0">false</dei:EntityEmergingGrowthCompany>
    <dei:AmendmentFlag contextRef="c0">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c0">0001326205</dei:EntityCentralIndexKey>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M4$L! A0#%     @ *(:L5 =!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  HAJQ4EPW,Q^X    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M"  HAJQ4F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( "B&K%1P'RC0.00  %D0   8
M      " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M"  HAJQ4GZ ;\+$"  #B#   #0              @ %\#   >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( "B&K%27BKL<P    !,"   +              "
M 5@/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( "B&K%0ZJJ+G0 $  #P"   /
M              "  4$0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  H
MAJQ4)!Z;HJT   #X 0  &@              @ &N$0  >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  HAJQ499!YDAD!  #/ P  $P
M            @ &3$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 )
+ #X"  #=$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="indiaglob20220512_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.igcinc.us/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="indiaglob20220512_8k.htm">indiaglob20220512_8k.htm</File>
    <File>ex_374886.htm</File>
    <File>igc-20220510.xsd</File>
    <File>igc-20220510_def.xml</File>
    <File>igc-20220510_lab.xml</File>
    <File>igc-20220510_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>picture2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "indiaglob20220512_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "local": [
      "igc-20220510_def.xml"
     ]
    },
    "inline": {
     "local": [
      "indiaglob20220512_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "igc-20220510_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "igc-20220510_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "igc-20220510.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "igc",
   "nsuri": "http://www.igcinc.us/20220510",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "indiaglob20220512_8k.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://www.igcinc.us/role/DocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "indiaglob20220512_8k.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.igcinc.us/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "igc_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.igcinc.us/20220510",
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001185185-22-000608-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001185185-22-000608-xbrl.zip
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M;,(J-;@]%)IT'L9I7F9\91QY/C/=R:NCU^OL?O1X/Z9EH9!II7'9U3/1W3U
MW?H]G D5QS)1:=G)>V&_L\N/RC6C>F)Q#HH$7.+=-"[U#CJ[!ZA+7RH8CQSH
MKEX"#SNW^M"M!!%5=9+8[V*YK8'^CRU _>OU&\J?X5]T.GQ/7I2-!_$[]""N
M$(AES%?]4:;(:K(.CL8O8Y>_E7FAA_,V5.LA#> *H9 +$Q?_'*M,@4X\A)42
MF1JJ+%,1HBPE R$-/L%]8) )_T*@Y$1&2JCA$*_S:X4&<?PB(E#DD'X&HBQ$
M;B\<,5!Q.D,$-?[M7 )#@QEO>=T@]-:U=PP->6"([>!;[]#J$+(O53%3*OD!
MR!(F^U;.Y%AF,0CB9VJ<E>((5@*H99AFHA]=RR0$BKP,-=H*ACI$A57)+!R+
M!H"&@6PM\!FTQ!&>/4DGH&<)G<"@"E)Y!2'YB1Z/U10HD@X%4"_U%RIC-@K'
M"7#=T3P0KU.XB!/[UFD2:4G-^VU&>%3H$ V@ ?%+ M2<Y2#?!F(LK]$.J(L<
M/H?)P-\+\59^_%AF@7@IDY$$YJ[$P\.]O<,'@?B;S.#HR(_0A^DJ4U.0W)!4
M*!3A?;8KWJ9SZ'$*$Q@$8C9.\6A&93S'*8_3#+8JHFFHR32=J8P_Q!$<P7T2
MZA@G\EXFD@W(8FLVUK"XZA-VA$J1R,<RCF&E8O@=!U#">68H-JY;7@Y^@Q-K
M<-"X]_@X4^DP@%4A_#;UEI=A" VD64ZCF:(MKL!IP,4%I))OT^/;L2/'P]/,
MV^_=;WU65L<@^DGT8S"'-W*22_%2IU-@$1/)QP 4=L;>O]- 0RH*"/XIR1<K
MDSE3/]!>FDU3CMJICCF_@Q=//RP"L;_7.Z@=2\;ZTS&I3NCQSGLX H$XC]-"
MG*6BOP,25"^ F1?R-XU&_K',Q_!G&2IX2Q=R,BTS"4<R'FOX("O&YN?C=SNB
M!Q\?/%@XR]A[I#,X2VEVW_U-XEWHSO7GCO3+5&8X<'%L&LJ[=9Z56J?S?/?D
MC7CU7]^<@*IPR3<5+HIE;1R0 DM]FEP#):1P19QGZ9 6'2\BG40RD[^5 F2[
MR41J"5=BZWK#8E<+??[ZRI>JD/9!:%/7()M-,=(F2Z>9!KK.0$SS+KZ/23K;
M&:<S=FO11^DL@7MMK*=(*[SK]F(,353/E#R4AD+86SED(!&,#J-UT"F6BGR"
M%#E)8Q66,9!7,M8#3=0[TW!T,%)N.BZ ;%6BX+4DA?T!,LQ#.1RF<72;:=>P
M&OX"/!5;<IMC?4*4$R8JUL0U8!CB6A=9RON OUS#SY-YG&K\/2I1,$E4F:5%
M^DF'=,'S89-PA\-"YE,CRD+#D4;!.*=3AC%$;HE@#:]1*LGG.08V13HG'1'%
M%#$N@>Q ;83UW1ILF\8G<F[6'\^E8,:(6N$([0/X+FB7.\W' UBZH39;(:?3
M&)X2GFX7R$<U-Z?:KYPF$R-/C(P WSC7 8=2P8+H:QV5L)-S>@7ZCGG^\3RH
M[4K]Y+,7V]N2IQW 8UK#"VCNOX-C+$=;<GL/]FLC_*P5J$BGU@3TV#1_5Y9#
MN?T[+(4XKIL&<[>"DF6\]UX8:8%INU\1/5S)NW#U[^\]Z.T=]!X_>DA::R3V
M'SS/R^D-DX+3H7:,I::W;S>?QHK6I&+\_#XT8#;P+8HAV$M@J?W,8V/O'1MS
M;(F.S7L%5SS\?,67KCD3SY;8/'WKWH:6;TG+@R[2,JB12**7!5TCYT=7"P0-
MS^Z?O@2"Z]W?>WAX>'!@J7K_RZ@:=8U%J@;Q][P<N '\^@$?[M_?ZST^?/1$
M]'MM-%]=W6&-YB>&YHL-S=\5S8?? <TS'T=2_^52/ GV#_:"1WN/Q<M],4)X
M-*ILB7@KDQ*%UX>DW!T&0)GP[_[>D\</#IY49'FIXJ'HY[F:#(">063U1<Q(
M:Z)2("I4-$&$,2)1EJ+.LZ'3NZ/3J(MT6I,SSLK) .3R_2<'#Q[N^93Y2@TR
M(LW]1T2;CW?K+)R_ZSU\<O_HS<E]>*&'\GB=JGO\:>_94CKV^>VQH>/C!AV?
M&SJNRQB[MZ#C'T,7)WM2317'E!2AS$ SANTH"UA%#5W 0,L(;4DEP3MK.B8M
M=*1RG;'6AU_/^5LX];CCWO=L6,$V!O "9J6(V;2%7ZH<EU_G8[;/R*$J6,-2
M:*"2(6][K6^G9?;C_\#%/E$9[G'OT3,T,>5*YNHV.G/_N&8I(,TQX:Y17V?]
MT[27!V@NXHG!S_E\,BW22<[F JECPND'WD3)RD\V?]9_+UG_W3HZN]QNTX)-
M][CL-#^02*9I5I!Q!#9W),V2(HD<9^7(/UOY;69[>N9/-]^V!K%?=B]WQ:LT
M99,;-QU-=$(I0>CDWJ+Q5\?]A;7D]<MAHV.)WU'^DA2(9) 24< [L&!#,0/*
M(282_/')G=7ZY\G!JI9#&186DIG#%;24CHZ#+]WOL\MJ6]%0HJBY:G]3^L7L
M\(]H^^-=;+$!5@\PWB)3-4MJW>X"5%,SK63%W-OW!;M,FS6&W+*[OA_MN]^*
MLP^_!N(*]^+5AXN3RA)K%B,@7^3(LH!K&9<DSL$!R.%Z-5R !$0O3Y&$ Y7A
M.0;N#(0?EF1]SP-K<0UUQ#M(B8]BF _VJ3-C&857T;1:C+.T'(TYE5'EMX?^
M)F5A-AV?\M!B-:)' Z0*&W!@=MT>5L]&F:N";B2/?]QH?/O:.[%:7 ]HPW(G
M(2GKYWL'YO<IG"7]Z>=[YM>\')I?;X<"6B9%WD8 O??B8 ,>6E,>P7RA"D&W
M[+!'L()&//I*';'KI4D>KJTBV</4?9W3))\[1(N#N8"R!DKDQ+N0>;G9C3M1
M,A'#,B-A*K/?,/8$>7X9&O=R3:H 00O>1?<4OEJ3^3R9+2#W&UX0I(UPX!2[
MRYI:29A.0,D(,8W>$,1#S8!NO/K2 ;JY\#("&1B%O-0,U8F[<HJ1O/ E2O4W
MR* D)Y*OD96OSTFB^*811-%;#5<>/%S4KP(0;CDDR9=0GY''[0_-\_93&])D
MYF9)[.5-KG00%O"<@T Q37,5W#P!$OLBX[5U2XP:4FS$A0Q;S5%!VL$4B# J
MI SV+(:WG^?R:;3Y',W@6WR.:V)IV/#2V_+2_4[S4L?W*BA?'2=H%WWPPN.J
M^ ,*A6*KTF*GXWE.M$WV%]2CLC31X79 (CZ" ZV^,#'92(FA(GZ#?R9,!;7@
M93P-*LX]E5/2C[%]PER(<3I#EB*S:,'&Q+W&<,8B:ZUP>B+*] Q[8OB"G8%;
M"S^!PN9 =NU 'GP?!]+8S"FC37Z3B,/J.+UL[9 6H$+8'43%@,CCS.T9J]F4
M1M@^',B<K>G>0:G#>\D -8<A9SJ/- O_>N']+$-P$KR.""@2KNQ\@AJL:=$>
M; !T.?,6;:(.28"!CTK+,(S"7CW: ?46X<DH:.  61JH;M2 &LS4#L@-)3(@
M^%&H3]*&NY-U#?8$\Q#0;UXSO(P;#M U#O#@^^  _C5TFTL9\;WFJB595U??
M+S]\E;V9/JPT(L-2K,P\TRAK4V +BN:8W"-;5)\V9Z5K9^7A=W!6%/EM46V[
MZ9[$\V'!-0'_9-/3>$*IKR0.0/'#4!<&?(=J6@2^:PA: 8T1_IL.AW1R4-O+
M94P?Y(B^K9T.D#S9&=HB<P>B_=XG5;V5(="Y14-U2<!7.RBR35 W9E@61XRZ
M*0X+_J4_FKM;#G**YL%K3V2</0_T;1XP])&6,=[-G$:I;BGYDM%O^$37^,3A
M5^037R$C;O/\.]'S)@XP2[,X@A53&_+K&OD]^CZNJ5=:Q='GE#DT0S9Q*VQ<
MQ@N&++[(U2MP@$$&!#>"90)G4UT65\&&77R+1I L]M PRSK#*7KH95R,X8<9
M4.Q P1!V KY)AAB-0B&C.R2$<LT:M'XZ&ZL;V')+*0VBTNHV![AK!_AQIP]P
M?XCQ/_6P>UYG$IP(32*\8[REM]D0PZ&*2+W#DN!$43I!4%9(C]),09?"AF.2
M+&I/+'1G7 LA!V\&E6B*-M-B7ODN@#GX0!5Z5@=5 2=0F'*@F,&W<[&UO[>-
MWX8F*FTVQC,6RJDN"'N7AA\#H4#'*[C;ZY183F;$.IZIJ0%5P#:@@8E-/B8X
M,D,H3128L,V8]='$_N9S*@OC^"W5,!8T!\,R!2@ZDVA+2PN<22]=49XNV[I@
M#+DWA'SY #ZW(N3J:5N/A>7 MZNABBTEPW'0!!O5X[BVF?5I.RDSA8[OD@-2
M\GQ%[:YP)\@N+GVRX>-=X^-/.LW'SQ3HI@K(MU2WL*@AF8ZR-,^%G( 41F<0
M]7L3?.OA!&IF<&.+  %K#*?-6M5U<IUBT/Q$)R6*<WCT0\2I@42'5C6R;&.L
M/-GP2E+QK3V_3 PT$<%L/)2M@400]:#8-LPQS%1$V3,(Z,IV]3A.9]8N,4TU
MGW4YD2.R6I0%14$%_ D<:.0,"[-X9OC4ZS0UIOI+D!]Q)E?RD_CGZ\NK?[5@
M=O-"%B4Y^F-US3CN"&4W%5G+@UF/0'A3H]A:[3QV(Y=2)& #3)8P+U*T#0S:
MI"J'.LG+3-JT)%B0,$<(-%MTPC0O<MLFF?H+D6-.$Q@.I4.@@3"B&%9[PY.Z
MQI,P_^\:&B=L<H*;]+WSUU<;>NL<O7U-_-Q7I+>SBP52BU228H0@Q6$EXJ*<
M*K6QOG:/XKJ-,O)3FF-1!HONN=E=XT !1EZHRB!7V!Y00)0FR8.U+W/+I]6C
MP(6;8;*]RF5IVD"!@C^ERL55BA?XZGZC@C%Y36:9+MB]DA$F$?4NG5.\P2[,
MS91EAA>739H'A,8Y&,E,$D2R0I$&&'[ XB&+*YA?Q'AHZI$.1NXCBR&BF=!9
M1;J:IV!1L!3&YTW)8>6R/=4B)GPM3[4'1LC\][",&FW\<<K[=B$0#]8A!.+!
M)@3B*X5 ?&V&Y_Y_<+B,^XD&3Q;(E/E-T(2P'(U)NIJKPL8959A$4B<_G%K5
M"W]%]ZX]V8KBK-A;W? 3/&-]"-]JPN1=RU-,RP2;;?S5$ZM(F>] K2UC-FLM
M;88Q5:ABK30><2,PW%I@Z#8*\FJLLT@T@S07901K.>7[OACS,[K.R?I8-SO*
M]3(ZWI4Z4-6H;,1F+12L_/9Y,K]Z:FO'@&OTUL:-[[W8W^U1BC>'SR'2(M\
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M4.^P=0 HR[E)9]'$_XFPS!#N,*_A\SG9V,B6 +*07\IXELW_V&AP%+OB1%(
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M&'Z:G4,#2R@9N_1(V6M71:S Y:U[M"O..,.62Y=MC/8U4Q9L4&HV<6$+N9
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MM9JY*!N\+W.-(5^"HXX0O\)5BJW*KDJ?[/%.\&ME3%0VPG\ES&$D;>U6=($
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M4?,2G:H9Y4N0%#I![EUV07.'(P2?)';5IBEZ4C$0&_A$I(UAQC*1,04=U -
M*!,.L21S858_>Y:G@7*I\5D4B=10EG'A!4X,;$8/N\Q#X/\(;DG#4.:,W:>!
M#-:F#N.&\7S/N;'PEJ]2P7CUXYFL\S*[UN9R]^76!6[TU"KMN>@%8C\0!UO1
M=B >!:C$]_;@__"X!\][!VP5Z#U8%P*_:VM=;Z]AKN/>CQF8B(<?U^/(R]6B
M5U]?9[U.^1J[=F#_T(!G-N?K'/8O'5.3=@0,<J=MC!T_81X+LQRLI;0:Q3[1
MJYJ243W=YV)K9T8T:M;;20S\S57.YD>5H.(O+T8TX&#H9%ML<53=\($%RG*Y
MU)A$D"D5D,;\FM471MHQ\H3M;]C4LBB;:%6M]1K+YZA/5-3;N5ZLT<(@OZQJ
M5S.BD*!71=.Y@/O*P0,"GT-NUX3()GJ;,R>VM^!"]$E BAR+,R:&!;&)8S1Q
MX"@GN1GY0S<XBH4&K6$W79!WPS2=*D*%H/YG@N=EI516&[AD&39\=_WX[E>U
MB'[I8,[I<!.KW=GP6.*Q!S2D*R_8O(HS=[YF9B!)2O6G*0F?D@PTXU/,3-,S
MG3H%5N<65EWC393&SX"?%]5C"D> .1(<UKBA;N!\M^!Z56C%8%[C=]*.W6=1
MVC.C_EX&9VS<EI.U?DG&,O61'/S7J:8@<-20)[##S?:^=DW3+Z.3;X4]>[P.
MV+/'&^S9&FIIO65:VA23%%RH/(W+#:YBC26$KXJK^-+!]+.!MG;*HUB6.9:5
M_0$%!:(7_P+H\05PRN;/B(\7&I0QC$F1]N6E,A'0)P*\$&,-:@WG;K&I/A>@
M=/6ZHG4$7JOCN+ IU]A;.E&^Q1S&8WRIWF::,@R^NB&GTU2CP(%5*<R;Z/RS
M"@H6KC/OH-_9O9$WOK<8O>J-52HBZT$6_K%I)&=M!0LIWV1IZ<%KPUC60E*G
M\4$?D\/UGCPY9 ?G-);L\NB[1:]( .=]K.*QKO8RELFHE"./3DZ24:SS\49G
M7,,;8:UTQG<4+WABP@DWMX%_[!=X*J8%<]'PY!E5)H>+%X])]7?(T08L/7%Y
MWPUC<-="%56;<:$;<D4F:I066E;1[@Y=OBLN"SF9BJA$RURF1I7'T9:JQO=9
M$?/*AU7%KNUK7H:8!LI<TZ44^,%*F'$==%-*SF\0"D:3_NZN@8;DO=\J>;\'
MU17XF$Q46FZ",=>5Q:Z5T'U.0ILQU)]G&G=GG?GLUW;RUOFL\!FM($Y[F]HI
MS)(0+R*O31(^%,W1PN4O[S0C@"0^I^0H&,R^/"TDE06C8(ZA!4><@A0N60J#
M01F_A>V"FW8-5X7.&*I%]3GPKUDMLK*>"V3#*=:*4ZR5,'9$I?L*,4NSCYST
MC:RW'/6TSBRCB]?]9\6_&O\ANSRE!#&6]_/Q[O$NC+.,R(X/3]Z>'?4O+T!1
M5J8&(^)I<2L9Y(T& I ?*1<VO(W@K5A.\V;55=7$N)K42OC-;*QC1KVX?M&O
MZ^=")-)AW)@FMI?KG%-H^;04>$:):9HCZ+7RYE*L8,'X.V?]P%GY^= 'MJI\
M2WHDPMZQE[-JTW#.(M.#TJ]?3</*QR9]KS?()>N0PB4P0EUWH5JM*]?9>^@R
M9%$4GVF0.'G5?F"6B25DIZ?;PBI6N\:5L+5*;/+$D<8*)Z:W@[UZ+LM:ES;*
MR)\)OV#WE'-15L,RBQLI6"G&#E()KJ)*OV-RN\F\\@9%-IE:XPK:7#EK>.5\
M52CPEPX&Y!TU21S!KO,E\VTO !;V(A $DRB@JG*X;";3"&;5%5A-B4Y[51O)
M<$P#\ZBBIXF/+;35TE2=O]51.(&+?S!V0)U9(S2"(PF=+"94BC@/&-=,/Y%9
M83*-TSE9+[SL3WZR)X[S0T.W+<C+ENY:B3J*?L]"G3N MLFR8D*?%](;M@7B
M4T*7SW33C,A:Q)TW+B'_]G#6TUOMGM_*W2\Y+_.6YR. <7(2+\Q3N,RZU)CM
M]LTK2)6Y,EE&'+F*(/X)*C$)5R4996F.(((1'!3GZZC[*6(YJQ6EY]!:JMB1
MTK]!S<U1Z)T!7/28F9(">_ !S"?+RBG=<=A<@)-83MMU[%FUE&X9@PJ@L8!%
MV[)9D1?J%#2HW)!K?3EK)<661.D&)O5R?9G\@;#(,Z-<16A!=!$\<%5[*>04
MUV;8TM?;?X32/^..63G/_%80BB?K *%XLH%0;.3&;D1R?.E@?C5\;2,P^@XC
MAD#+_$9NORC3>1%D*=YQ2^4([_*S%H" @LH**YHDB*K+<H;_457BAF)/XD2A
MJ!2ZO9U0&34WV$>- I+!'(+<08A(!#A SUI%_C4/>CP%F'FUC.OM34 T',.O
MIG80L%)=4%UH$XF+?B2L78QJ?S9-\Z6Y87.N2=.0<6)75MY4)U88^IUCP4_%
MH7R9R[6-UA:DQUUQBF'T D-TBRI8^.[W@VH^N]Q,L(@$W>?ZIR[.D4S8D9S(
M47-#JE57\'8Z04@GO<?@D]]*+@8]S1"9R66:1 SR(SZ!55^ILV[#T+]%1?LO
M'<Q%"Z/XU1WG#9OWV+S3*AUS-476>;EROTQ+E2NNJO/%.F8Z2Y3+(X9G/W.9
M"@I=Q,HR$%,<1C-LJ*Y0^X4V6Y646BJ[6EV"9Y2PK2J0([EVEZ>X-W4ET@-M
M;K-*]_+3JN(KBU4O6T=656NN#\R87#-E$!1#Z/)6"=U\'0DF%VX;L +C[*6Q
MPI#)V3Y+7%D<H]J:YF8)J]A5.E5G'JZGDJH&6T'PK;MQ,2<ZI[IEO^70I$,/
MS.4*LH(S4K>M8FV]O&11]01157XH6(%H&V_"!/OV9J.68-::T6=?O(]D++?Z
M=X &![*C3S/.Y6X)B *_KG6*MSG-'"D^QNHA)2<RYPN-LSO6 N#,HV$]2[DI
M7Z>H>IV?TRK#"]%=J^=.>&@?/2P'9HRG5-R4,R5UU."0.U690LX;PC'T=/OI
M! U_E,,&GD*[7 O/O4%D JR#RO5][TB:@V9BP->P'AF!(2Q*\L=&TJQQ^H!.
MI@4\:TDW@J69*=,4XJEKL:BF](N,:#8Y'7G8^8]R9$Z_#0/+TDF*% V4ZZQT
M2V!^MM+%(N8$7T$%!M]:'AJ[+ED(-N?D>TZ-UWI.$N^20F(E[XB)621JG;F8
M:?O$!%XKK!J))V*4IA'FD"E:4^=M:GAWE<@[F<2JD2,VE(G)BB3S'%YM"=]U
M+-H@5 C.\OET!E3"N%8YB"#B(.>-4KI)5#,3)8^@Z=]!A]VG;9!JV^I(6)2)
MR="P-=_&PM55I:?&W]&S])]MEGA5AAF>J/A&9CV-G-4;!XRV)SCQ5D<:E+E.
MC.T/AJF*O-DTG'-R4'&!.;MFZ0!S7MK)>ZOCX=U;EG/#"CK&"CJ;5LKF :#L
MD.0 I#MK,5(?DQE3K1:,!DS)\$P9 ,BR34;925E08$0@KM.X3 I.P4]1&$,#
M#L! $5*$\>DU97@S\5_VP%"Z-4Q?&G#Z 3(7A"FB*LR;G+& 86&?KQZ#SH>"
M'/]RD%XK#XR";,]7M&\RH&S.8\?.XU>U):_R/-:RUG*TD\F8/,.*I%-;)7L
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M,I..F4HFYMR+.\A/LOCXVW^.18S[%1;'IO8A!CP>QMN@,82AQEC8%WSC1O?
M7ZO%P8%\C,__(?4WWQ YXW8<?FZ<J4@,4%)D/J*>K<+^J^\\&21J2X*-CUT-
MSDV=8Y08!U.+$W0.B7USM=@)O ZZ?@_KJ*>[8FG(!8-(%GTU9?4K+"_WY*._
M+O!$M00#P+55P1 L4@-26\G!20*OIW%>Q-9]F!)?OE[4Z%S9\DB"B8C4:94%
M41@'(=+]JFW+/O_C+)*;P6IMWOY:\?\ 4$L#!!0    ( "B&K%0\,O/*[ 4
M  4J   4    :6=C+3(P,C(P-3$P7V1E9BYX;6S56MERXC@4?>^O\'A>9BKE
MF)V&"M-%01:'$-) UJZN*6,+4-J6:$EFR=>/Y(7&P3@-=J;BIQ!;.CHZY_I*
M5_;)EZ5M27- *,2H(>>/<[($D(%-B"8-^7:@- <M39.__"-)GT[^4!3I'"!
M= 9,:;226MB>#0PH#8F.Z!@36_J+V7]+BC1E;%97U<5B<6SP-M2 !%#L$ -0
M<4%2% X80+8($(!U:3AUI*Z^DO(%J9"K%POU4E&Z';;X/X6"U^73B071CY%.
M@<1Y(]J0-T9:CHAUC,E$+>1R135H*'LMZTMQ(=1^471;YVNUFNK>73>E,*HA
MA\VK#]VK@3$%MJY 1)F.##$ A77J7KS"ALY<)=_D)>UL(?Y3@F:*N*3D"THQ
M?[RDYIHB;V.R]3"; &75NRD+O23IA& +],%8<J=89ZL9:,@4VC-+,'>O30D8
M-V0X,12A=*Z<SXFA_FQCP[$!8DUDGB(&V4I#PF-W@K(D8&_[6FBF' (BX]BA
MJKBKQ@*H/CV=&+_+<(=BP82%5&67N0GYL"*B%1.,=<=BLN0/L\EXC0$14WD7
MU6^C;G?G9/\'KMC6(3J8JM=;]1ZL=R([Y1#$<$9 60^\']\H (_R^PGL"J/8
MP!X!LJ>ZH:XNS_=BJ5O6?MQ$AS4C'J<00?%<7?&Q0ZS D@%D C/@)3H?_- &
MP<6'M+ 1&L<2J0^38!A+'P&K(9L _AL@;@!QED!CP*;;:M%@TA08QQ,\5SF$
M*O*2^.$F*,_5MX #;9)2'>JC*%.3T?1 ?P5^R,(F"=/EC@?C^^;_7G3X?<8$
MV[]O!,-O*8&)"4A#YAL%+X;K!D:,1]FI!40'_AR B?CQZ[Z%*3 ;,B,.^)6?
M]O+%B\0^F$#*^%Z#7>MV,D\B ?TE*74S7F6@)+9$"^%;DH^1?%_%^99.[ $'
M*WN$K412AY$VR'Q8D5_-W5>WL%/=0[/,D+=+);.X0&LB'U;7\+Q]68MQ>6)O
M:9L<WQ1CG%GZ))&V8:0LA.VKN?OZEE(+6R_WM/@ 1+<TOJ=8=L JA2S\&G%S
MB?BP8N\0PQ>]G.;B%]"Z 01BOBDSV[Q<3B5OA!$SH?L.,7S=*^EO.DYM0"9\
M-3@G>,&FXL1#1VE$?33NQT_BL:KX-E13S>E!&6)@,L/$93=@W/46=OC3MVIA
M,XV]8#Q^9K:&;\CD&_0Y;J?H'LI]N^_>E;]_>S!FSO(1E6OF2W4^>5RAV[:S
M.*^26K53>+X=KJA5G1LO.>N2U9QYGUX.'[J@"Q97JXO:1>>YHE5FH[G17CY?
M-:]Z=IF--7H]^+EHEYKXY4D]JY5*CY^KX]Y8RZU*7UNHN%CEYO>/NG'7&?2(
M5E@>E:LW+W<5<WGQ>-3^01]ZG7Z'M%H+ZYP]WC&@6O:I>4T[3^?7Z*BCM\UY
MZ6?'*;:JIX-R?E"Y=\YN?SY5AQA<5E5D]F;:"^KG6E^'9_,75BQ4G@K=^>7T
MZ+R[:E].>Q55FYX!8/?.>HMBO_\\OGMB\+O4&O2]H\>#HO8,6N#:V30W08AN
M@&4B5V]+X(=?+?TT/=27FLEYP3'TCF!34WT7\CM6[ZE[L%.=H'+,Q26$@PQI
MFB8!E/I_!+]\"F9$H68F-T=*$C@05[PGLZ#%?_;($"]0>@9L8&:A--JI1Z#^
M[N(^F?;N"MPC-P3/H?>N*"4#7@-GSH4M90(K8@X$$EEQ@RG3K2<X2VG#& F;
MH74Y6I; A=W'!H?D(_'(-0G0$TL? OKXQ5)XWH&VNT\']M55O&^V;J88I;')
MW ++1#!O2Q#(''L8L+?4]P0R!A O=6T'^;NH9*^OHA$S(?H.,0+ETZW_!]B"
M!E<!3;I\R2!03_8^(@(N"XMGE J!WC'E_+YBWQ @7 5\27:/ZL6[8](;CQ/F
MEAC83 1\G"R!"[%5;5(C-$H=0-[)CFWPC[^TOJU/\-YN=VV[=R8"AL,SWRI?
M& TA2_A9P!98)AZ$;0D"F6,+V(.E/ET:4QU-0.(W_I& &3@ZB!8B$#VF;O6^
M#%+#GP;Y9IRL/T,4 OP'4$L#!!0    ( "B&K%3?W?!580@  $E5   4
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M,3!?<')E+GAM;-5:6W/:.!A][Z_PLB^[TW',-00F28<Q(76!D(#)K=/9,;8
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M!)]2.EQ[G6"-^;QN[<QLX?.I0++B]_M<8A6#H'P3O4,[WXM )FNI1JI)JOW
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M!RES&)$V[71\UYD27K^JJ5<LX*$GI]1OE<QNH1JU0!H6.+>+>Z(37D,&CN=
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M[L82"[&4OQBGK1M;G3T26\T'49O&2JDC&07W< PK9BA%1IQ>LS)@*F;;ARE
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M12,I,$Z,#2+1T\71@^VG PEPD3^SB? 3JK/BE 1->P<S\S8<+N09LT(G9YL
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M>%\S-S0X.#8N:'1M4$L! A0#%     @ *(:L5&FTUD4Y!   NPP  !
M         ( !SS<  &EG8RTR,#(R,#4Q,"YX<V102P$"% ,4    "  HAJQ4
M/#+SRNP%   %*@  %               @ $V/   :6=C+3(P,C(P-3$P7V1E
M9BYX;6Q02P$"% ,4    "  HAJQ4W]WP56$(  !)50  %
M@ %40@  :6=C+3(P,C(P-3$P7VQA8BYX;6Q02P$"% ,4    "  HAJQ4%Z\<
M5*,%  !4*P  %               @ 'G2@  :6=C+3(P,C(P-3$P7W!R92YX
M;6Q02P$"% ,4    "  HAJQ4, /&\.82  "?:0  &               @ &\
M4   :6YD:6%G;&]B,C R,C U,3)?.&LN:'1M4$L! A0#%     @ *(:L5&OH
MZ9C-%0  ;!8   P              ( !V&,  '!I8W1U<F4R+FIP9U!+!08
1    !P ' +\!  #/>0     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
